Compare SPIR & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SPIR | CTNM |
|---|---|---|
| Founded | 2012 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 347.1M | 416.1M |
| IPO Year | N/A | 2024 |
| Metric | SPIR | CTNM |
|---|---|---|
| Price | $10.41 | $9.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 5 |
| Target Price | $12.10 | ★ $18.60 |
| AVG Volume (30 Days) | ★ 906.7K | 290.2K |
| Earning Date | 12-17-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.81 | N/A |
| Revenue | ★ $77,387,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.87 | N/A |
| P/E Ratio | $11.80 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.60 | $3.35 |
| 52 Week High | $21.43 | $14.90 |
| Indicator | SPIR | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 64.58 | 30.36 |
| Support Level | $7.36 | $11.66 |
| Resistance Level | $9.72 | $11.73 |
| Average True Range (ATR) | 0.67 | 0.80 |
| MACD | 0.27 | -0.35 |
| Stochastic Oscillator | 93.97 | 12.86 |
Spire Global Inc is a provider of space-based data, analytics, and Space Services, offering datasets and powerful insights about Earth from the ultimate vantage point of space so that organizations can make decisions with confidence, accuracy, and speed. It generates revenue from four solutions: Maritime, Aviation, Weather, and Space Services. It offers the following three data solutions to customers; Maritime-precise space-based data used for accurate ship monitoring, ship safety, and route optimization, Aviation-precise space-based data used for accurate aircraft monitoring, aircraft safety, and route optimization, and Weather-precise space-based data used for accurate weather forecasting.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.